M&T Bank
CLDX icon

M&T Bank’s Celldex Therapeutics CLDX Stock Holding History

M&T Bank’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-653
Closed -$247K – 1837
2015
Q2 		$247K Sell
653
-11
-2% -$4.37K ﹤0.01% 1621
2015
Q1 		$278K Sell
664
-77
-10% -$27.5K ﹤0.01% 1507
2014
Q4 		$204K Sell
741
-161
-18% -$40K ﹤0.01% 1752
2014
Q3 		$175K Buy
+902
New +$197K ﹤0.01% 1922
2014
Q2 		– Sell
-4
Closed -$1K – 1096
2014
Q1 		$1K Buy
+4
New +$1.53K ﹤0.01% 1179

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

M&T Bank's CLDX Position: Q3 2015 in Review

M&T Bank sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 653 shares — an estimated $247K sold.

M&T Bank first reported a position in CLDX in Q1 2014 and held it in 5 quarters. The position peaked at $278K in Q1 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • M&T Bank reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • M&T Bank sold 653 Celldex Therapeutics shares in Q3 2015, an estimated $247K.
  • M&T Bank first reported a position in Celldex Therapeutics in Q1 2014 and held it in 5 quarters.
  • M&T Bank's Celldex Therapeutics position peaked at $278K in Q1 2015.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on M&T Bank's 13F filing for Q3 2015, filed 13 Nov 2015.